Strategic Signals Weekly

Lisata Therapeutics, Inc. terminated its merger agreement with Kuva Labs Inc. after Kuva failed to obtain sufficient financing for the tender offer. Kuva is obligated to pay Lisata a $2 million termination fee, and Lisata reserves rights to seek further damages. Lisata's Board will now assess strategic options to enhance stockholder value, including reverse mergers, asset sales, or dissolution, with no assurance of a successful outcome.

New Freenome completed its business combination, establishing post-merger governance and equity structures. This included an amendment to the Business Combination Agreement to reduce the board to seven directors, alongside new Investor Rights and Lock-Up Agreements. Shareholders also approved a 2026 Equity Incentive Plan and Employee Stock Purchase Plan to manage equity compensation.

MannKind Corporation completed a private placement, raising approximately $50.0 million in gross proceeds through the issuance of common stock and pre-funded warrants to institutional accredited investors. The company plans to use these proceeds for general corporate purposes, including a $45.0 million contingent value rights payment due to the recent FDA approval of Furoscix ReadyFlow™ (furosemide injection) for edema in adults with heart failure or chronic kidney disease.

Dyne Therapeutics priced an underwritten public offering of 18.3 million shares of common stock at $20.50 per share, expecting net proceeds of approximately $352.1 million. This financing, combined with existing cash and a recent $50 million loan, is projected to fund the company's operations into the second quarter of 2028.

Alzamend Neuro, Inc. announced the passing of Dr. Lynne Fahey McGrath, a director, on July 20, 2026. Dr. McGrath had served on the Board of Directors since the company's initial public offering in June 2021, and the company expressed profound sadness, highlighting her significant contributions to corporate governance and biopharmaceutical knowledge.